KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Operating Leases (2019 - 2025)

Amneal Pharmaceuticals has reported Operating Leases over the past 7 years, most recently at $58.8 million for Q4 2025.

  • Quarterly results put Operating Leases at $58.8 million for Q4 2025, up 25.01% from a year ago — trailing twelve months through Dec 2025 was $58.8 million (up 25.01% YoY), and the annual figure for FY2025 was $58.8 million, up 25.01%.
  • Operating Leases for Q4 2025 was $58.8 million at Amneal Pharmaceuticals, up from $26.4 million in the prior quarter.
  • Over the last five years, Operating Leases for AMRX hit a ceiling of $64.0 million in Q4 2021 and a floor of $8.5 million in Q1 2025.
  • Median Operating Leases over the past 5 years was $27.2 million (2024), compared with a mean of $32.1 million.
  • Biggest five-year swings in Operating Leases: skyrocketed 92.75% in 2024 and later plummeted 68.19% in 2025.
  • Amneal Pharmaceuticals' Operating Leases stood at $64.0 million in 2021, then fell by 7.45% to $59.2 million in 2022, then decreased by 17.42% to $48.9 million in 2023, then decreased by 3.84% to $47.0 million in 2024, then rose by 25.01% to $58.8 million in 2025.
  • The last three reported values for Operating Leases were $58.8 million (Q4 2025), $26.4 million (Q3 2025), and $27.6 million (Q2 2025) per Business Quant data.